Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 81M | 54M | 59M | 51M | 54M |
| Gross Profit | 61M | 46M | 52M | 44M | 47M |
| Operating Income | -2M | -12M | -201K | -501K | -5M |
| EBITDA | -1M | -9M | 4M | 3M | -3M |
| Net Income | -20M | -18M | -4M | -5M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$5.54
-0.18% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alimera Sciences, Inc. (ALIM) is a Healthcare stock with a market cap of $301.29M. The stock last traded around $5.54. Baseline metrics include revenue growth of +49.2%, EPS growth of +69.5%, a dividend yield of 0.0%. What stands out right now is revenue +49.2%, EPS +69.5%, free cash flow -777.7% with operating margin -2.4% and ROIC -1.5%. Valuation is more restrained than many high-expectation growth names at price/sales 3.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ALIM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ALIM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ALIM Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ALIM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$53.9M
+6.1% YoY
FY Net Income
-$10.4M
-95.6% YoY
Free Cash Flow
-$4.3M
-53.8% YoY
Revenue Growth
+49.2%
EPS Growth
+69.5%
Gross Margin
75.7%
Net Margin
-24.9%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 81M | 54M | 59M | 51M | 54M |
| Gross Profit | 61M | 46M | 52M | 44M | 47M |
| Operating Income | -2M | -12M | -201K | -501K | -5M |
| EBITDA | -1M | -9M | 4M | 3M | -3M |
| Net Income | -20M | -18M | -4M | -5M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12M | 5M | 17M | 11M | 9M |
| Total Assets | 154M | 43M | 59M | 51M | 50M |
| Total Liabilities | 107M | 63M | 61M | 59M | 55M |
| Shareholder Equity | 46M | -21M | -3M | -8M | -4M |
| Total Debt | 67M | 44M | 44M | 45M | 39M |
| Net Debt | 55M | 39M | 27M | 34M | 30M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
-89.3% YoY
Capital Expenditures
174K
+71.9% YoY
Free Cash Flow
4M
-53.8% YoY
Key ratios
Gross Margin
75.7%
Operating Margin
-2.4%
Net Margin
-24.9%
ROE
-159.0%
Debt / Equity
1.46x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.